Veracyte Inc (NASDAQ:VCYT) CEO Bonnie H. Anderson sold 8,000 shares of Veracyte stock in a transaction dated Monday, August 12th. The stock was sold at an average price of $25.28, for a total value of $202,240.00. Following the sale, the chief executive officer now directly owns 121,414 shares of the company’s stock, valued at approximately $3,069,345.92. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
NASDAQ VCYT opened at $24.88 on Friday. Veracyte Inc has a 1-year low of $8.77 and a 1-year high of $31.18. The stock has a 50-day moving average of $27.73 and a 200-day moving average of $24.30. The firm has a market cap of $1.20 billion, a PE ratio of -40.13 and a beta of 0.96.
Veracyte (NASDAQ:VCYT) last announced its quarterly earnings results on Tuesday, July 30th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.04. Veracyte had a negative return on equity of 10.26% and a negative net margin of 11.01%. The company had revenue of $30.14 million for the quarter, compared to the consensus estimate of $29.20 million. On average, sell-side analysts anticipate that Veracyte Inc will post -0.23 earnings per share for the current year.
A number of equities research analysts have recently weighed in on the company. ValuEngine lowered Veracyte from a “strong-buy” rating to a “buy” rating in a research note on Thursday, August 1st. BidaskClub lowered Veracyte from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 3rd. Zacks Investment Research raised Veracyte from a “hold” rating to a “buy” rating and set a $27.00 target price for the company in a research note on Saturday, May 4th. Lake Street Capital assumed coverage on Veracyte in a research note on Wednesday, July 31st. They issued a “buy” rating and a $35.00 target price for the company. Finally, Needham & Company LLC set a $34.00 target price on Veracyte and gave the company a “buy” rating in a research note on Wednesday, July 31st. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. Veracyte has a consensus rating of “Buy” and a consensus target price of $25.06.
Veracyte Company Profile
Veracyte, Inc operates as a genomic diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas solutions for a complex landscape in thyroid nodule diagnosis to physicians; Percepta Bronchial Genomic Classifier solution for use in lung cancer diagnosis; and Envisia Genomic Classifier solution for the diagnosis of idiopathic pulmonary fibrosis.
Read More: How does a reverse stock split work?
Receive News & Ratings for Veracyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veracyte and related companies with MarketBeat.com's FREE daily email newsletter.